Report on hearing loss in oncology

Cisplatin is used frequently as an antineoplastic drug in the treatment of many different cancers. However, when used in doses over 360mg/m(2), ototoxicity may ensue, resulting in loss of hearing. Criteria for identifying and quantifying hearing loss have been devised. AIM: To describe the features...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultz, Christiane, Goffi-Gomez, Maria Valéria Schmidt, Pecora Liberman, Patrícia Helena, Carvalho, André Lopes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442188/
https://www.ncbi.nlm.nih.gov/pubmed/19893928
http://dx.doi.org/10.1016/S1808-8694(15)30510-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442188/
https://www.ncbi.nlm.nih.gov/pubmed/19893928
http://dx.doi.org/10.1016/S1808-8694(15)30510-3

Ejemplares similares